The results of the CRISPR screen support a framework in which LCS3 disrupts redox homeostasis in sensitive LUAD cell lines and highlights NQO1 activity as a key determinant of LCS3 sensitivity and a potential biomarker for response
If you notice cloudiness, discoloration, or particles, do not use the vial and contact PlexusDx support immediately
Fatigue and weakness may occur, particularly during the initial treatment period as the body adjusts to the metabolic effects of the medication
However, symptoms such as nausea, reflux, bloating, burping, abdominal discomfort or diarrhoea may disturb sleep, especially if they happen after eating late or lying down soon after a meal
Intravital dynamic pressure measurements in lumbar discs